Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer

Zhang, Minghai; Cheng, Shanshan; Jin, Yue; Zhao, Yaqian; Wang, Yu

doi:10.1016/j.bbcan.2021.188503

Cited by 176 publications

(145 citation statements)

References 102 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…Additionally, the experience of a sonographer is often the primary limiting factor in the evaluation of ovarian masses, as it may affect the diagnostic performance of ultrasound. Moreover, since the levels of CA125 were reported to increase in both benign lesions and other types of ovarian tumors, CA125 may not be effective in discriminating benign from malignant tumors [ 19 ]. To the best of our knowledge, few studies have investigated whether a combination of CA125 and US classification increases the preoperative accuracy of differentiating benign from malignant adnexal masses.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses

et al. 2022

View full text Add to dashboard Cite

Objective Ovarian cancer is the most deadly deadliest gynecological tumor in the female reproductive system. Therefore, the present study sought to determine the diagnostic performance of International Ovarian Tumor Analysis Simple Rules (IOTA SR), the Ovarian-Adnexal Reporting and Data System (O-RADS), and Cancer Antigen 125 (CA125) in discriminating benign and malignant ovarian tumors. The study also assessed whether a combination of the two ultrasound categories systems and CA125 can improve the diagnostic performance. Methods A total of 453 patients diagnosed with ovarian tumors were retrospectively enrolled from Fujian Cancer Hospital between January 2017 and September 2020. The data collected from patients included age, maximum lesion diameter, location, histopathology, levels of CA125, and detailed ultrasound reports. Additionally, all ultrasound images were independently assessed by two ultrasound physicians with more than 5 years of experience in the field, according to the IOTA simple rules and O-RADS guidelines. Furthermore, the area under the curve (AUC), sensitivity, and specificity of the above mentioned predictors were calculated using the receiver operating characteristic curve. Results Out of the 453 patients, 184 had benign lesions, while 269 had malignant ovarian tumors. In addition, the AUCs of IOTA SR, O-RADS, and CA125 in the overall population were 0.831, 0.804, and 0.812, respectively, and the sensitivities of IOTA SR, O-RADS, and CA125 were 94.42, 94.42, and 80.30%, respectively. On the other hand, the AUCs of IOTA SR combined with CA125, O-RADS combined with CA125, and IOTA SR plus O-RADS combined with CA125 were 0.900, 0.891, and 0.909, respectively. The findings also showed that the AUCs of a combination of the three approaches were significantly higher than those of individual strategies (p<0.05) but not significantly higher than the AUC of a combination of two methods (p>0.05). Conclusion The findings showed that a combination of IOTA SR or O-RADS in combination with CA125 may improve the ability to distinguish benign from malignant ovarian tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As in our patient's case, the ultrasound image of atypical polypoid adenomyoma and carcinosarcoma are very similar (Figure 4). Histopathologically, the mechanism of malignancy is not well-known [20][21][22][23]. Matsumoto et al found adenocarcinoma type malignancy after atypical adenomyoma treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, he admits hysteroscopy as being a very successful procedure in the detection of endometrial lesions [ 7 , 16 ]. Evaluation of the endometrium by hysteroscopy D and C raises the accuracy in diagnosis of endometrial cancer [ 7 , 17 , 18 , 19 , 20 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Atypical Polypoid Adenomyoma of the Vagina: Follow Up and Subsequent Evolution: A Case Report and Update

et al. 2022

View full text Add to dashboard Cite

Atypical polypoid adenomyoma (APA) is a rare tumor developed from a mix of cells of epithelial and mesenchymal origin. We present the case of an 84-year-old patient with atypical polypoid adenomyoma on the vaginal vault, after total hysterectomy with total adnexectomy for endometrial hyperplasia with atypia four years ago. Not following regular indicated gynecological appointments, the symptoms presented were vaginal bleeding and anemia. The importance of the case consists both in the unique way in which the adenomyoma appears on the vaginal vault and in the subsequent evolution of this pathology. After complete resection, it recurs in five months with a malignant transformation into carcinosarcoma. This fact shows that adenomas can turn not only into carcinomas but also the mesenchymal component can progress to sarcoma, a fact of exceptional rarity. Follow-up and accurate diagnosis are essential for proper management, which is a challenge anyway due to the lack of case studies.

show abstract

“…The level of CA125 correlates with the stage of the disease and increases at the later stages. However due to its insufficient specificity this marker is not always detected at the early stages [ 4 ]. Other markers including HE4 (Human epididymis protein 4), CA72-4 (carbohydrate antigen 72–4), CA15-3 (carbohydrate antigen 15–3), CEA (carcinoid embryonic antigen), CA19-9 (carbohydrate antigen 19–9), and others are overexpressed in ovarian cancer and also don't exhibit a sufficient sensitivity and specificity for the diagnosis and prognosis of ovarian cancer [ [5] , [6] , [7] , [8] ].…”

Section: Introductionmentioning

confidence: 99%

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer

Nurgalieva¹,

Popov²,

Skripova³

et al. 2021

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

The high mortality rate from ovarian cancer is due to the asymptomatic nature of the course of the disease, which leads to the diagnosis of ovarian cancer in later stages. The sodium-dependent phosphate transporter NaPi2b encoded by SLC34A2 gene is expressed in 80–90% of epithelial ovarian cancers and used as a target for therapeutic antibodies XMT-1536, and XMT-1592, which are derived from MX35 antibodies and used in clinical trials for the treatment of ovarian and lung cancers. In this work, we aimed to evaluate NaPi2b as a molecular marker for diagnostics and predicting the course and outcome of ovarian cancer disease. Quantitative analysis of SLC34A2 gene expression in ovarian tumor tissue was performed at the level of transcription and translation using real-time PCR, droplet digital PCR and Western blot analysis respectively. Statistical analysis was performed taking into account various clinicopathological characteristics of the ovarian cancer patients, including the stage of the disease, the tumor grade, the applying of neoadjuvant chemotherapy and the presence of ascites. In this work, we demonstrated that the expression of the human NaPi2b (hNaPi2b) transporter is downregulated in the tumors of patients receiving neoadjuvant therapy and during the development of disease. The data suggest that the level of expression of the SLC34A2 gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.

show abstract

Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer

Cited by 176 publications

References 102 publications

Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses

Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses

Atypical Polypoid Adenomyoma of the Vagina: Follow Up and Subsequent Evolution: A Case Report and Update

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer

Contact Info

Product

Resources

About